Biogen, EMA and FDA

Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
But now the bad news for patients and healthcare systems: Biogen's list-price annual cost of Spinraza (nusinersen) will be $750,000 for six jabs in the first year of treatment. Although Biogen ...
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...
Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...